Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|
Factor | N | HR (95% CI) | P value | HR (95% CI) | P value |
Treatment | |||||
PTR | 42 | Reference | 0.093 | Reference | 0.495 |
USC | 15 | 1.76 (0.87 to 3.35) | 1.30 (0.60 to 2.73) | ||
Age | |||||
<63 years | 30 | Reference | 0.923 | - | - |
≥63 years | 27 | 0.97 (0.52 to 1.80) | |||
Sex | |||||
Male | 15 | Reference | 0.116 | - | - |
Female | 42 | 1.70 (0.84 to 3.24) | |||
BMI | |||||
<22 kg/m2 | 33 | Reference | 0.627 | - | - |
≥22 kg/m2 | 24 | 0.85 (0.44 to 1.61) | |||
Tumor location | |||||
Colon | 35 | Reference | 0.280 | - | - |
Rectum | 22 | 0.70 (0.35 to 1.32) | |||
KRAS status | |||||
Wild type | 30 | Reference | 0.001 | Reference | 0.004 |
Mutant or unknown | 27 | 2.81 (1.49 to 5.31) | 2.89 (1.41 to 6.02) | ||
CEA | |||||
<5.1 | 10 | Reference | 0.822 | - | - |
≥5.1 | 47 | 1.09 (0.53 to 2.56) | |||
Invasion depth | |||||
T1-3 | 24 | Reference | 0.0540 | Reference | 0.065 |
T4a, T4b | 33 | 1.93 (0.99 to 3.87) | 1.97 (0.96 to 4.24) | ||
Lymph node metastasis | |||||
Negative | 6 | Reference | 0.225 | - | - |
Positive | 51 | 2.47 (0.89 to 10.2) | |||
Sum of the longest diameters of metastases | |||||
<67 mm | 29 | Reference | 0.184 | - | - |
≥67 mm | 28 | 1.52 (0.82 to 2.87) | |||
Number of metastases | |||||
<13 | 29 | Reference | 0.084 | Reference | 0.199 |
≥13 | 28 | 1.72 (0.93 to 3.24) | 1.55 (0.79 to 3.09) | ||
Number of organs with metastasis | |||||
1 | 22 | Reference | 0.010 | Reference | 0.037 |
≥2 | 35 | 2.52 (1.26 to 5.48) | 2.14 (1.04 to 4.76) | ||
Peritoneal dissemination | |||||
No | 48 | Reference | 0.129 | - | - |
Yes | 9 | 1.90 (0.76 to 4.16) | |||
Total lines of chemotherapy | |||||
1 to 2 | 35 | Reference | 0.111 | - | - |
≥3 | 22 | 0.60 (0.31 to 1.13) | |||
Use of anti-VEGF antibody | |||||
No | 12 | Reference | 0.403 | - | - |
Yes | 45 | 0.71 (0.34 to 1.69) | |||
Use of anti-EGFR antibody (KRAS wild patient only) | |||||
No | 8 | Reference | 0.197 | - | - |
Yes | 22 | 2.22 (0.73 to 9.59) |